

Research Transparency Panel

Meeting Summary

Date: 30th November 2023

Time: 15:00-16:00

Data Access Proposal Request	
Company: Roche	Flatiron Health UK RWD products: <ul style="list-style-type: none"> ● Non Small Cell Lung Cancer ● Breast Cancer ● Prostate Cancer ● Multiple Myeloma ● Chronic Lymphocytic Leukaemia ● Diffuse Large Cell Lymphoma
Attendees:	
<u>Flatiron Health UK</u> Adam Manhi (<i>chair</i>) Liv Bryan (<i>program manager</i>)	<u>Research Transparency Panel</u> Jennifer McCaffery (<i>lay</i>), Kaeden Bunting (<i>lay</i>), Thomas Smith (<i>patient</i>), Sonia Patton (<i>patient</i>) & Yanrong Jiang (<i>clinical</i>)
Conflicts of Interest:	No conflicts declared by panel
Decision Outcome:	APPROVED
<p>Summary of discussion:</p> <ul style="list-style-type: none"> - Comprehensive lay summary using understandable, plain language - Broad number of use cases selected and evidenced to demonstrate patient benefit - A concise summary of analytics approaches and rationale by use case highlighted - Research benefits clearly outlined for patients, but also for the UK healthcare ecosystem (e.g. cost-effectiveness assessment) <p>The panel raised several comments on other aspects of the application including:</p> <ul style="list-style-type: none"> - Specific examples of the current unmet needs across tumour types would have been helpful - Content and language was lengthy at points and could benefit from being more concise - More clarity needed around the potential impact of RWD insights on specific patient cohorts and their treatments / outcomes - Inclusion of examples of target outputs (e.g. conferences like ESMO) where insights will be shared further - Full completion of the form required (i.e. the applicant had missed a verification step in the form inadvertently) 	